KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Payables (2016 - 2025)

Biolife Solutions (BLFS) has disclosed Payables for 16 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Payables fell 55.77% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 55.77% year-over-year, with the annual reading at $1.5 million for FY2025, 55.77% down from the prior year.
  • Payables for Q4 2025 was $1.5 million at Biolife Solutions, down from $2.9 million in the prior quarter.
  • The five-year high for Payables was $15.5 million in Q1 2023, with the low at $1.5 million in Q4 2025.
  • Average Payables over 5 years is $8.1 million, with a median of $7.4 million recorded in 2021.
  • The sharpest move saw Payables surged 507.05% in 2021, then crashed 85.23% in 2023.
  • Over 5 years, Payables stood at $14.9 million in 2021, then grew by 2.82% to $15.4 million in 2022, then crashed by 85.23% to $2.3 million in 2023, then soared by 48.02% to $3.4 million in 2024, then crashed by 55.77% to $1.5 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $1.5 million, $2.9 million, and $3.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.